These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. de Kleijn ED; de Groot R; Hack CE; Mulder PG; Engl W; Moritz B; Joosten KF; Hazelzet JA Crit Care Med; 2003 Jun; 31(6):1839-47. PubMed ID: 12794428 [TBL] [Abstract][Full Text] [Related]
8. Purpura fulminans in children: report of two cases. Hwang CC; Jaing TH; Chiu CH Acta Paediatr Taiwan; 1999; 40(2):119-20. PubMed ID: 10910600 [TBL] [Abstract][Full Text] [Related]
9. [Meningococcal purpura fulminans: treatment with recombinant protein C activator in 3 cases]. Salinas U; Unzueta J; Vidarte MA; Rodrigo MP; Gómez JJ; Aguilera L Rev Esp Anestesiol Reanim; 2007 Oct; 54(8):503-6. PubMed ID: 17993100 [TBL] [Abstract][Full Text] [Related]
10. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Nadel S; De Munter C; Britto J; Habibi P; Levin M Crit Care Med; 1998 May; 26(5):971-2; author reply 972-3. PubMed ID: 9590331 [No Abstract] [Full Text] [Related]
11. Acute meningococcaemia: recent advances in management (with particular reference to children). Kennedy NJ; Duncan AW Anaesth Intensive Care; 1996 Apr; 24(2):197-216. PubMed ID: 9133195 [No Abstract] [Full Text] [Related]
12. Purpura fulminans localising to a recent burn injury. Wharton SM; Reid CA Burns; 1998 Nov; 24(7):680-2. PubMed ID: 9882071 [TBL] [Abstract][Full Text] [Related]
13. [Value of heparin in the treatment of meningococcal purpura fulminans. 3 cases]. Charlas J; Thieffry JC; Madelin JC; Dardenne P; Meyer B; Paupe J; Vialatte J Ann Pediatr (Paris); 1970; 17(8):553-9. PubMed ID: 5455263 [No Abstract] [Full Text] [Related]
14. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Fourrier F; Leclerc F; Aidan K; Sadik A; Jourdain M; Tournoys A; Noizet O Intensive Care Med; 2003 Jul; 29(7):1081-7. PubMed ID: 12761614 [TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601 [No Abstract] [Full Text] [Related]
16. The Inflammatory and Hemostatic Response in Sepsis and Meningococcemia. Boeddha NP; Bycroft T; Nadel S; Hazelzet JA Crit Care Clin; 2020 Apr; 36(2):391-399. PubMed ID: 32172820 [TBL] [Abstract][Full Text] [Related]
18. [Meningococcal purpura fulminans: untoward result of genetic polymorphism?]. Mercier JC; Bingen E; Schlegel N; Elion J; Casanova JL; Mira JP; Beaufils F Arch Pediatr; 2001 Aug; 8(8):843-52. PubMed ID: 11524916 [TBL] [Abstract][Full Text] [Related]
19. Thrombolytic therapy in adult meningococcal purpura fulminans with acute renal failure and severe perfusion deficits to the extremities. Pechlaner C; Buratti T; Biedermann H; Joannidis M; Wiedermann CJ Wien Klin Wochenschr; 1999 Sep; 111(16):650-4. PubMed ID: 10510843 [TBL] [Abstract][Full Text] [Related]
20. Recombinant tissue plasminogen activator in children with meningococcal purpura fulminans--role uncertain. Baines P; Carrol ED Crit Care Med; 2004 Aug; 32(8):1806-7. PubMed ID: 15286574 [No Abstract] [Full Text] [Related] [Next] [New Search]